These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14996767)

  • 21. Cost-effectiveness of olanzapine as a first-line treatment: a comment.
    Basu A
    Value Health; 2006; 9(5):357; author reply 358. PubMed ID: 16961554
    [No Abstract]   [Full Text] [Related]  

  • 22. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olanzapine and haloperidol for residual symptoms.
    de Haan L; van Beveren N
    Am J Psychiatry; 2005 Jul; 162(7):1392-3; author reply 1393. PubMed ID: 15994737
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
    Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olanzapine treatment of residual positive and negative symptoms.
    Buchanan RW; Ball MP; Weiner E; Kirkpatrick B; Gold JM; McMahon RP; Carpenter WT
    Am J Psychiatry; 2005 Jan; 162(1):124-9. PubMed ID: 15625210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: Olanzapine versus haloperidol.
    Boulay LJ; Labelle A; Bourget D; Robertson S; Habib R; Tessier P; Tombaugh T; Milin R
    Cogn Neuropsychiatry; 2007 Jul; 12(4):322-38. PubMed ID: 17558641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical antipsychotics and formulary decisions.
    Am J Manag Care; 1998 Jan; 4 Suppl():S8-12; discussion S12-4. PubMed ID: 10184948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-benefits of risperidone.
    Bilsker D
    Psychiatr Serv; 1996 Mar; 47(3):309-10. PubMed ID: 8820560
    [No Abstract]   [Full Text] [Related]  

  • 30. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
    Rosenheck R; Cramer J; Xu W; Thomas J; Henderson W; Frisman L; Fye C; Charney D
    N Engl J Med; 1997 Sep; 337(12):809-15. PubMed ID: 9295240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olanzapine for injection: new formulation. No advantage in agitated patients.
    Prescrire Int; 2004 Jun; 13(71):92-3. PubMed ID: 15233144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olanzapine monotherapy for late-onset vocal tics in a schizophrenic patient.
    Cheng WJ; Liu HC; Huang MC
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):700-1. PubMed ID: 18081638
    [No Abstract]   [Full Text] [Related]  

  • 33. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia.
    Tunis SL; Johnstone BM; Gibson PJ; Loosbrock DL; Dulisse BK
    J Clin Psychiatry; 1999; 60 Suppl 19():38-45; discussion 46. PubMed ID: 10507279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia.
    Battaglia J; Houston JP; Ahl J; Meyers AL; Kaiser CJ
    Clin Ther; 2005 Oct; 27(10):1612-8. PubMed ID: 16330297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.
    Vera-Llonch M; Delea TE; Richardson E; Rupnow M; Grogg A; Oster G
    Value Health; 2004; 7(5):569-84. PubMed ID: 15367252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
    Volavka J; Nolan KA; Kline L; Czobor P; Citrome L; Sheitman B; Lindenmayer JP; McEvoy J; Lieberman JA
    Schizophr Res; 2005 Jul; 76(1):127-9. PubMed ID: 15927808
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.
    Oh PI; Iskedjian M; Addis A; Lanctôt K; Einarson TR
    Can J Clin Pharmacol; 2001; 8(4):199-206. PubMed ID: 11743592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
    Hamilton SH; Revicki DA; Genduso LA; Beasley CM
    Neuropsychopharmacology; 1998 Jan; 18(1):41-9. PubMed ID: 9408917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olanzapine and haloperidol in first episode psychosis: two-year data.
    Green AI; Lieberman JA; Hamer RM; Glick ID; Gur RE; Kahn RS; McEvoy JP; Perkins DO; Rothschild AJ; Sharma T; Tohen MF; Woolson S; Zipursky RB;
    Schizophr Res; 2006 Sep; 86(1-3):234-43. PubMed ID: 16887334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
    Kahn RS; Fleischhacker WW; Boter H; Davidson M; Vergouwe Y; Keet IP; Gheorghe MD; Rybakowski JK; Galderisi S; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Grobbee DE;
    Lancet; 2008 Mar; 371(9618):1085-97. PubMed ID: 18374841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.